tbuckley/cabot-search huggingface dataset:
Genome-scale CRISPR screens identify host factors that promote human coronavirus infection
Authors: Marco Grodzki, Andrew P. Bluhm, Moritz Schaefer, Abderrahmane Tagmount, Max Russo, Amin Sobh, Roya Rafiee, Chris D. Vulpe, Stephanie M. Karst, Michael H. Norris
Journal: Genome Medicine (2022)

Abstract Background The COVID-19 pandemic has resulted in 275 million infections and 5.4 million deaths as of December 2021. While effective vaccines are being administered globally, there is still a great need for antiviral therapies as antigenically novel SARS-CoV-2 variants continue to emerge across the globe. Viruses require host factors at every step in their life cycle, representing a rich pool of candidate targets for antiviral drug design. Methods To identify host factors that promote SARS-CoV-2 infection with potential for broad-spectrum activity across the coronavirus family, we performed genome-scale CRISPR knockout screens in two cell lines (Vero E6 and HEK293T ectopically expressing ACE2) with SARS-CoV-2 and the common cold-causing human coronavirus OC43. Gene knockdown, CRISPR knockout, and small molecule testing in Vero, HEK293, and human small airway epithelial cells were used to verify our findings. Results While we identified multiple genes and functional pathways that have been previously reported to promote human coronavirus replication, we also identified a substantial number of novel genes and pathways. The website https://sarscrisprscreens.epi.ufl.edu/ was created to allow visualization and comparison of SARS-CoV2 CRISPR screens in a uniformly analyzed way. Of note, host factors involved in cell cycle regulation were enriched in our screens as were several key components of the programmed mRNA decay pathway. The role of EDC4 and XRN1 in coronavirus replication in human small airway epithelial cells was verified. Finally, we identified novel candidate antiviral compounds targeting a number of factors revealed by our screens. Conclusions Overall, our studies substantiate and expand the growing body of literature focused on understanding key human coronavirus-host cell interactions and exploit that knowledge for rational antiviral drug development.
Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
Authors: Maria C Cid, Sebastian H Unizony, Daniel Blockmans, Elisabeth Brouwer, Lorenzo Dagna, Bhaskar Dasgupta, Bernhard Hellmich, Eamonn Molloy, Carlo Salvarani, Bruce C Trapnell, Kenneth J Warrington, Ian Wicks, Manoj Samant, Teresa Zhou, Lara Pupim, John F Paolini
Journal: Annals of the Rheumatic Diseases (2022)

Objectives Granulocyte-macrophage colony-stimulating factor (GM-CSF) is implicated in pathogenesis of giant cell arteritis. We evaluated the efficacy of the GM-CSF receptor antagonist mavrilimumab in maintaining disease remission. Methods This phase 2, double-blind, placebo-controlled trial enrolled patients with biopsy-confirmed or imaging-confirmed giant cell arteritis in 50 centres (North America, Europe, Australia). Active disease within 6 weeks of baseline was required for inclusion. Patients in glucocorticoid-induced remission were randomly assigned (3:2 ratio) to mavrilimumab 150 mg or placebo injected subcutaneously every 2 weeks. Both groups received a 26-week prednisone taper. The primary outcome was time to adjudicated flare by week 26. A prespecified secondary efficacy outcome was sustained remission at week 26 by Kaplan-Meier estimation. Safety was also assessed. Results Of 42 mavrilimumab recipients, flare occurred in 19% (n=8). Of 28 placebo recipients, flare occurred in 46% (n=13). Median time to flare (primary outcome) was 25.1 weeks in the placebo group, but the median was not reached in the mavrilimumab group (HR 0.38; 95% CI 0.15 to 0.92; p=0.026). Sustained remission at week 26 was 83% for mavrilimumab and 50% for placebo recipients (p=0.0038). Adverse events occurred in 78.6% (n=33) of mavrilimumab and 89.3% (n=25) of placebo recipients. No deaths or vision loss occurred in either group. Conclusions Mavrilimumab plus 26 weeks of prednisone was superior to placebo plus 26 weeks of prednisone for time to flare by week 26 and sustained remission in patients with giant cell arteritis. Longer treatment is needed to determine response durability and quantify the glucocorticoid-sparing potential of mavrilimumab. Trial registration number ClinicalTrials.gov number: NCT03827018 , Europe (EUdraCT number: 2018-001003-36), and Australia (CT-2018-CTN-01 865-1).
EPR22-104: A Comparison of the Burden of Leukemia Amongst Various Regions of the World, 1990-2019
Authors: Alaaeldin Ahmed, Chinmay Jani, Padmanabh Bhatt, Harpreet Singh, Ruchi Jani, Joseph Shalhoub, Dominic Marshall, Prudence Lam, Justin Salciccioli
Journal: Journal of the National Comprehensive Cancer Network (2022)
FEMORAL VASCULAR CLOSURE DEVICES AND BLEEDING, HEMOSTASIS, AND AMBULATION FOLLOWING PERCUTANEOUS CORONARY INTERVENTION
Authors: Laurie-Anne Boivin Proulx, Guillaume Marquis-Gravel, Zhen Huang, Steven L. Zelenkofske, A. Michael Lincoff, Roxana Mehran, Philippe Gabriel Steg, Christoph Bode, John H. Alexander, Thomas Joseph Povsic
Journal: Journal of the American College of Cardiology (2022)
VALIDATION OF THE STS/ACC TVT RISK SCORE IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT STRATIFIED BY RISK
Authors: Karim Al-Azizi, Emily Shih, John Squiers, Srinivasa P. Potluri, Molly Szerlip, William Brinkman, Justin Michael Schaffer, Katherine Harrington, Timothy A. Mixon, Robert C. Stoler, William H. Ryan, Anita R. Krueger, Mohanad Hamandi, Jasjit K. Banwait, J. Michael DiMaio, Michael J. Mack
Journal: Journal of the American College of Cardiology (2022)
National health and budget impact of implementing the WHO HEARTS hypertension control program in Bangladesh
Authors: Anirudh Pidugu, Sarah Pickersgill, David Watkins, Jami Husain, Deliana Kostova, Margaret Farrell, Mohammad Haider, Shamim Jubayer, Renesa Tarannum, Mahfuzur Bhuiyan, Andrew E. Moran, Sohel Choudhury
Journal: The Lancet Global Health (2022)

About a fifth of adults in Bangladesh have hypertension; only 13% of Bangladesh adults living with hypertension have their blood pressure controlled (<140/90 mmHg). To address the growing burden of hypertension in low-income and middle-income countries, the WHO recommends implementing the HEARTS technical package. HEARTS outlines a practical approach to cardiovascular disease (CVD) prevention in primary care settings, including risk factor screening, diagnosis, treatment, and patient counseling. The Bangladesh Ministry of Health and Family Welfare and the National Heart Foundation of Bangladesh implemented the HEARTS programme in four district health complexes in Sylhet Division starting in 2019. To inform Bangladesh's health care policies, we translated Bangladesh HEARTS programme effectiveness and cost estimates into projections of national health and budget impact for nationwide programme scale-up.We used an interactive, web-based model to project CVD deaths averted based on observed facility-based hypertension control rates and used local costs to obtain budget impact estimates of national HEARTS programme implementation. We also explored three alternative scenarios: reducing medication costs by 50%, increasing team-based care with larger roles for nurses and community health workers, and removing laboratory costs. Relative improvement in hypertension control observed in the HEARTS programme (from 26% to 46% in the four districts over 24 months) was applied to the 13% baseline national control rate resulting in a projected improvement to 33% at national scale. The costs of the hypertension programme were quantified with a standard HEARTS costing tool that was deployed in the four district health complexes. The costing tool recorded and calculated unit costs for hypertension screening, CVD risk assessment, health-care worker time or compensation, and drug prices.An absolute improvement of 20 percentage points in the national hypertension control rate, from 13% to 33%, would save 9400 lives. Extrapolating local programme costs to the national level resulted in a budget of US$599 million by 2030. Reducing medication costs would lower the budget impact by 42·6%. Increasing team-based care would not substantively affect the cost. Removing laboratory costs would lower the budget by 14%. Combining these innovations would lower the projected cost by 56·9%.Implementing the HEARTS programme in Bangladesh might improve hypertension control and save 9400 lives at a budget impact of $599 million by 2030. Increased task sharing and lower medication prices have potential to reduce costs and make reaching hypertension control goals more affordable and sustainable for Bangladesh.Columbia University Global & Population Health Summer Research Fellowship.
Aerobic exercise elicits clinical adaptations in myotonic dystrophy type 1 patients independently of pathophysiological changes
Authors: Andrew I. Mikhail, Peter L. Nagy, Katherine Manta, Nicholas Rouse, Alexander Manta, Sean Y. Ng, Michael F. Nagy, Paul Smith, Jian-Qiang Lu, Joshua P. Nederveen, Vladimir Ljubicic, Mark A. Tarnopolsky
Journal: Journal of Clinical Investigation (2022)

BackgroundMyotonic dystrophy type 1 (DM1) is a complex life-limiting neuromuscular disorder characterized by severe skeletal muscle atrophy, weakness, and cardiorespiratory defects. Exercised DM1 mice exhibit numerous physiological benefits that are underpinned by reduced CUG foci and improved alternative splicing. However, the efficacy of physical activity in patients is unknown.MethodsEleven genetically diagnosed DM1 patients were recruited to examine the extent to which 12 weeks of cycling can recuperate clinical and physiological metrics. Furthermore, we studied the underlying molecular mechanisms through which exercise elicits benefits in skeletal muscle of DM1 patients.RESULTSDM1 was associated with impaired muscle function, fitness, and lung capacity. Cycling evoked several clinical, physical, and metabolic advantages in DM1 patients. We highlight that exercise-induced molecular and cellular alterations in patients do not conform with previously published data in murine models and propose a significant role of mitochondrial function in DM1 pathology. Finally, we discovered a subset of small nucleolar RNAs (snoRNAs) that correlated to indicators of disease severity.ConclusionWith no available cures, our data support the efficacy of exercise as a primary intervention to partially mitigate the clinical progression of DM1. Additionally, we provide evidence for the involvement of snoRNAs and other noncoding RNAs in DM1 pathophysiology.Trial registrationThis trial was approved by the HiREB committee (no. 7901) and registered under ClinicalTrials.gov (NCT04187482).FundingNeil and Leanne Petroff. Canadian Institutes of Health Research Foundation (no. 143325).
Association of Cardiac Biomarkers With Cardiovascular Outcomes in Patients With Psoriatic Arthritis and Psoriasis: A Longitudinal Cohort Study
Authors: Keith Colaco, Ker‐Ai Lee, Shadi Akhtari, Raz Winer, Paul Welsh, Naveed Sattar, Iain B. McInnes, Vinod Chandran, Paula Harvey, Richard J. Cook, Dafna D. Gladman, Vincent Piguet, Lihi Eder
Journal: Arthritis & Rheumatology (2022)

In patients with psoriatic disease (PsD), we determined whether cardiac troponin I (cTnI) and N-terminal pro-brain natriuretic peptide (NT-proBNP) were associated with carotid plaque burden and the development of cardiovascular events independent of the Framingham Risk Score (FRS).Among 1,000 patients with PsD, carotid total plaque area (TPA) was measured in 358 participants at baseline. Cardiac troponin I and NT-proBNP were measured using automated clinical assays. The association between cardiac biomarkers and carotid atherosclerosis was assessed by multivariable regression after adjusting for cardiovascular risk factors. Improvement in the prediction of cardiovascular events beyond the FRS was tested using measures of risk discrimination and reclassification.In univariate analyses, cTnI (β coefficient 0.52 [95% confidence interval (95% CI) 0.3, 0.74], P < 0.001) and NT-proBNP (β coefficient 0.24 [95% CI 0.1, 0.39], P < 0.001) were associated with TPA. After adjusting for cardiovascular risk factors, the association remained statistically significant for cTnI (adjusted β coefficient 0.21 [95% CI 0, 0.41], P = 0.047) but not for NT-proBNP (P = 0.21). Among the 1,000 patients with PsD assessed for cardiovascular risk prediction, 64 patients had incident cardiovascular events. When comparing a base model (with the FRS alone) to expanded models (with the FRS plus cardiac biomarkers), there was no improvement in predictive performance.In patients with PsD, cTnI may reflect the burden of atherosclerosis, independent of traditional cardiovascular risk factors. Cardiac troponin I and NT-proBNP are associated with incident cardiovascular events independent of the FRS, but further study of their role in cardiovascular risk stratification is warranted.
Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study
Authors: Daniel J Sheward, Changil Kim, Roy A Ehling, Alec Pankow, Xaquin Castro Dopico, Robert Dyrdak, Darren P Martin, Sai T Reddy, Joakim Dillner, Gunilla B Karlsson Hedestam, Jan Albert, Ben Murrell
Journal: The Lancet Infectious Diseases (2022)
BET Protein Inhibition for Pulmonary Arterial Hypertension: A Pilot Clinical Trial
Authors: Steeve Provencher, François Potus, Pascale Blais-Lecours, Sarah Bernard, Sandra Martineau, Sandra Breuils-Bonnet, Jason Weatherald, Mike Sweeney, Ewelina Kulikowski, Olivier Boucherat, Sebastien Bonnet
Journal: American Journal of Respiratory and Critical Care Medicine (2022)

"BET Protein Inhibition for Pulmonary Arterial Hypertension: A Pilot Clinical Trial." American Journal of Respiratory and Critical Care Medicine, 205(11), pp. 1357–1360
EFFECTS OF HOME-BASED ISOMETRIC HANDGRIP TRAINING OR AEROBIC TRAINING ON OFFICE BLOOD PRESSURE AMONG OLDER ADULTS WITH HIGH NORMAL BP TO ESTABLISHED HYPERTENSION -PRELIMINARY RESULTS OF THE HOLDAGE TRIAL
Authors: Diogo Pinto, Nuno Dias, Catarina Garcia, Manuel Teixeira, Elisa A. Marques, Maria J. Marques, Teresa Amaral, Leonor Amaral, Pedro Ruivo, Ricardo Abreu, Cristiana Carneiro, Ana P. Oliveira, Daniela Figueiredo, Jorge Polónia, José Mesquita-Bastos, João L. Viana, Linda S. Pescatello, Fernando Ribeiro, Alberto J. Alves
Journal: Journal of the American College of Cardiology (2022)
Chromatin domain alterations linked to 3D genome organization in a large cohort of schizophrenia and bipolar disorder brains
Authors: Kiran Girdhar, Gabriel E. Hoffman, Jaroslav Bendl, Samir Rahman, Pengfei Dong, Will Liao, Mads E. Hauberg, Laura Sloofman, Leanne Brown, Olivia Devillers, Bibi S. Kassim, Jennifer R. Wiseman, Royce Park, Elizabeth Zharovsky, Rivky Jacobov, Elie Flatow, Alexey Kozlenkov, Thomas Gilgenast, Jessica S. Johnson, Lizette Couto, Mette A. Peters, Jennifer E. Phillips-Cremins, Chang-Gyu Hahn, Raquel E. Gur, Carol A. Tamminga, David A. Lewis, Vahram Haroutunian, Stella Dracheva, Barbara K. Lipska, Stefano Marenco, Marija Kundakovic, John F. Fullard, Yan Jiang, Panos Roussos, Schahram Akbarian
Journal: Nature Neuroscience (2022)
WORSE OUTCOMES IN OBESE YOUNG ADULTS HOSPITALIZED WITH COVID-19
Authors: Jessica Weinberg, Janet Kandrevas, Xiaokui Gu, Allison Brook, Armaghan Ahmad, Akshay Reddy, Emma Morganroth, Kacie Alexander, Matthew Benson, Nadia Razaq Sutton, Eva M. Kline-Rogers
Journal: Journal of the American College of Cardiology (2022)
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update
Authors: Andrea Eisen, Mark R. Somerfield, Melissa K. Accordino, Phillip S. Blanchette, Mark J. Clemons, Sukhbinder Dhesy-Thind, Melissa S. Dillmon, Stella D'Oronzo, Glenn G. Fletcher, Elizabeth S. Frank, Sigrun Hallmeyer, Issam Makhoul, Beverly Moy, Alia Thawer, Joy Y. Wu, Catherine H. Van Poznak
Journal: Journal of Clinical Oncology (2022)

PURPOSE To update recommendations of the American Society of Clinical Oncology (ASCO)-Ontario Health (Cancer Care Ontario [CCO]) adjuvant bone-modifying agents in breast cancer guideline. METHODS An Expert Panel conducted a systematic review to identify new, potentially practice-changing data. RESULTS Four articles met eligibility criteria and form the evidentiary basis for revision of the previous recommendations. RECOMMENDATIONS Adjuvant bisphosphonate therapy should be discussed with all postmenopausal patients (natural or therapy-induced) with primary breast cancer, irrespective of hormone receptor status and human epidermal growth factor receptor 2 status, who are candidates to receive adjuvant systemic therapy. Adjuvant bisphosphonates, if used, are not substitutes for standard anticancer modalities. The benefit of adjuvant bisphosphonate therapy will vary depending on the underlying risk of recurrence and is associated with a modest improvement in overall survival. The NHS PREDICT tool provides estimates of the benefit of adjuvant bisphosphonate therapy and may aid in decision making. Factors influencing the decision to recommend adjuvant bisphosphonate use should include patients' risk of recurrence, risk of side effects, financial toxicity, drug availability, patient preferences, comorbidities, and life expectancy. When an adjuvant bisphosphonate is used to prevent breast cancer recurrence, the therapeutic options recommended by the Panel include oral clodronate, oral ibandronate, and intravenous zoledronic acid. The Panel supports starting bisphosphonate therapy early, consistent with the points outlined in the parent CCO-ASCO guideline; this is a consensus recommendation. The Panel does not recommend adjuvant denosumab to prevent breast cancer recurrence, because studies did not show a consistent reduction of breast cancer recurrence in any subset of those with early-stage breast cancer. Additional information can be found at www.asco.org/breast-cancer-guideline .
CONCORDANT LOW AND DISCORDANT FRACTIONAL FLOW RESERVE AND INSTANTANEOUS WAVE-FREE RATIO MEASUREMENTS ARE ASSOCIATED WITH REDUCED MYOCARDIAL PERFUSION:A COMPARISON BETWEEN PRESSURE RATIO MEASUREMENTS AND 15O-WATER PET PERFUSION IMAGING
Authors: Ruben Willem De Winter, Pepijn Van Diemen, Stefan Schumacher, Ruurt Jukema, Yvemarie Somsen, Michiel Bom, Henk Everaars, Albert van Rossum, Niels Verouden, Pieter Raijmakers, Alexander Nap, Roel Driessen, Ibrahim Danad, Paul Knaapen
Journal: Journal of the American College of Cardiology (2022)
Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial
Authors: Veronique De Jager, Nikhil Gupte, Silvia Nunes, Grace L. Barnes, Rob Christiaan van Wijk, Joni Mostert, Susan E. Dorman, Ahmed A. Abulfathi, Caryn M. Upton, Alan Faraj, Eric L. Nuermberger, Gyanu Lamichhane, Elin M. Svensson, Ulrika S. H. Simonsson, Andreas H. Diacon, Kelly E. Dooley
Journal: American Journal of Respiratory and Critical Care Medicine (2022)

Rationale: Carbapenems are recommended for treatment of drug-resistant tuberculosis. Optimal dosing remains uncertain. Objectives: To evaluate the 14-day bactericidal activity of meropenem, at different doses, with or without rifampin. Methods: Individuals with drug-sensitive pulmonary tuberculosis were randomized to one of four intravenous meropenem-based arms: 2 g every 8 hours (TID) (arm C), 2 g TID plus rifampin at 20 mg/kg once daily (arm D), 1 g TID (arm E), or 3 g once daily (arm F). All participants received amoxicillin/clavulanate with each meropenem dose. Serial overnight sputum samples were collected from baseline and throughout treatment. Median daily fall in colony-forming unit (CFU) counts per milliliter of sputum (solid culture) (EBACFU0–14) and increase in time to positive culture (TTP) in liquid media were estimated with mixed-effects modeling. Serial blood samples were collected for pharmacokinetic analysis on Day 13. Measurements and Main Results: Sixty participants enrolled. Median EBACFU0–14 counts (2.5th–97.5th percentiles) were 0.22 (0.12–0.33), 0.12 (0.057–0.21), 0.059 (0.033–0.097), and 0.053 (0.035–0.081); TTP increased by 0.34 (0.21–0.75), 0.11 (0.052–0.37), 0.094 (0.034–0.23), and 0.12 (0.04–0.41) (log10 h), for arms C–F, respectively. Meropenem pharmacokinetics were not affected by rifampin coadministration. Twelve participants withdrew early, many of whom cited gastrointestinal adverse events. Conclusions: Bactericidal activity was greater with the World Health Organization–recommended total daily dose of 6 g daily than with a lower dose of 3 g daily. This difference was only detectable with solid culture. Tolerability of intravenous meropenem, with amoxicillin/clavulanate, though, was poor at all doses, calling into question the utility of this drug in second-line regimens. Clinical trial registered with www.clinicaltrials.gov (NCT03174184).
Comments on Surgeon-Patient Sex Concordance and Postoperative Outcomes
Authors: Xing Jin, Cheng Zhan, Qun Wang
Journal: JAMA Surgery (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
FULLY AUTOMATED 3D SEGMENTATION AND QUANTITATION OF THE AMYLOIDOPHILIC RADIOTRACER IODINE EVUZAMITIDE (124I-P5+14, AT-01) IN THE HEART OF PATIENTS WITH SYSTEMIC AMYLOIDOSIS AND HEALTHY SUBJECTS
Authors: Amy Weisman, Emily Martin, Robert Eric Heidel, Timothy G. Perk, Deepak Behera, Stephen Kennel, Jonathan Wall
Journal: Journal of the American College of Cardiology (2022)
Exaggerated false positives by popular differential expression methods when analyzing human population samples
Authors: Yumei Li, Xinzhou Ge, Fanglue Peng, Wei Li, Jingyi Jessica Li
Journal: Genome biology (2022)

Abstract When identifying differentially expressed genes between two conditions using human population RNA-seq samples, we found a phenomenon by permutation analysis: two popular bioinformatics methods, DESeq2 and edgeR, have unexpectedly high false discovery rates. Expanding the analysis to limma-voom, NOISeq, dearseq, and Wilcoxon rank-sum test, we found that FDR control is often failed except for the Wilcoxon rank-sum test. Particularly, the actual FDRs of DESeq2 and edgeR sometimes exceed 20% when the target FDR is 5%. Based on these results, for population-level RNA-seq studies with large sample sizes, we recommend the Wilcoxon rank-sum test.
Antigen vs RT-PCR Tests for Screening Quarantined Students in Florida During the COVID-19 Pandemic SARS-CoV-2 Delta Variant Surge
Authors: Eric J. Nelson, Sarah Lindley McKune, Kathleen A. Ryan, Jerne Shapiro, Adrienne H. Mott-Young, Paul D. Myers, J. Glenn Morris
Journal: JAMA Pediatrics (2022)

This diagnostic/prognostic study compares the results of antigen vs real-time reverse transcription–polymerase chain reaction tests among quarantined students 5 days after exposure to SARS-CoV-2 during the surge of Delta variant cases in the COVID-19 pandemic.